Keywords: مهار کننده پروتئازوم; Multiple myeloma; Bortezomib; Carfilzomib; Proteasome inhibitor;
مقالات ISI مهار کننده پروتئازوم (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده پروتئازوم; BTZ; bortezomib; CFZ; carfilzomib; C-L; caspase-like; CNS; central nervous system; CT-L; chymotrypsin-like; CYPs; cytochrome P450 enzymes; iP; immunoproteasome; IXZ; ixazomib; MM; multiple myeloma; OPZ; oprozomib; PD; pharmacodynamic; PI; proteasome inhib
Keywords: مهار کننده پروتئازوم; Quinolin-chlorobenzothioate; Proteasome inhibitor; Hypoxia; Endoplasmic reticulum stress; Glycolysis; Pancreatic cancer;
Keywords: مهار کننده پروتئازوم; Monoclonal antibody; Nanoparticle albumin-bound drug; Tyrosine kinase inhibitor; Immunomodulatory drug; Proteasome inhibitor; Cancer therapeutics; Targeted therapy; Nursing care;
Keywords: مهار کننده پروتئازوم; ASCT; autologous stem cell transplant; CR; complete response; CT; computed tomography; DPd; daratumumab, pomalidomide, and dexamethasone; DRd; daratumumab, lenalidomide, and dexamethasone; DVd; daratumumab, bortezomib, and dexamethasone; ERd; elotuzumab,
Keywords: مهار کننده پروتئازوم; Proteasome inhibitor; Peptide proline-boronic acid; Antitumor activity; Subunit selectivity; Synthesis;
Keywords: مهار کننده پروتئازوم; Urea-containing peptide boronic acids; Proteasome inhibitor; Anti-tumor activity; Structure-activity relationship; Low toxicity;
Keywords: مهار کننده پروتئازوم; TF, tissue factor; TFPI, tissue factor pathway inhibitor; EP, electrostatic potential; mTOR, mammalian target of rapamycin; ER stress, reticulum endoplasmic stress; ROS, reactive oxygen speciesAmblyomin-X; TFPI-like; Proteasome inhibitor; Autophagy inhibi
Keywords: مهار کننده پروتئازوم; Proteasome inhibitor; Auditory hair cell; Peroxisome dysfunction; Hearing loss;
Keywords: مهار کننده پروتئازوم; Carfilzomib; proteasome inhibitor; heart failure; chemotherapy
Keywords: مهار کننده پروتئازوم; Clinical trials; Dose-response relationship; Hematologic malignancy; Overall response rate; Post hoc analysis; Proteasome inhibitor
Keywords: مهار کننده پروتئازوم; Multiple myeloma; Immunomodulatory drug; Proteasome inhibitor;
Keywords: مهار کننده پروتئازوم; Ac2; EpCAM-binding DARPin; ATCC; American Type Culture Collection; Avi tag; peptide tag that is biotinylated by BirA; BirA; E. coli biotin ligase; CPP; cell-penetrating peptide; DARPin; designed ankyrin repeat protein; Ec1; EpCAM-binding DARPin; EpCAM; ep
Keywords: مهار کننده پروتئازوم; Proteasome inhibitor; Resistance; Multiple myeloma; Leukemia; Bortezomib
Keywords: مهار کننده پروتئازوم; Carfilzomib; Proteasome inhibitor; Hepatocellular carcinoma
Keywords: مهار کننده پروتئازوم; syringolin; syrbactin; proteasome inhibitor; virulence factor; type III effectors
Keywords: مهار کننده پروتئازوم; Multiple myeloma; Proteasome inhibitor; Therapy; Oral administration; Bortezomib; Carfilzomib; Marizomib; Ixazomib; Delanzomib;
Keywords: مهار کننده پروتئازوم; Carfilzomib; Proteasome inhibitor; Relapsed; Refractory; Newly-diagnosed; Multiple myeloma; Dosing; Schedule;
Keywords: مهار کننده پروتئازوم; Proteasome inhibitor; Bortezomib; Proteotoxic stress; Sensory ganglia neuron; Nucleolus; Cajal body
Keywords: مهار کننده پروتئازوم; Multiple myeloma; Proteasome inhibitor; Bone-targeted; Bisphosphonate conjugate; Boronic acid;
Keywords: مهار کننده پروتئازوم; Late stage of pressure overload; Heart failure; Collagen expression; Proteasome inhibitor; NF-κB;
Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma
Keywords: مهار کننده پروتئازوم; Autologous stem cell transplantation; Peripheral neuropathy; Proteasome inhibitor; Risk status; Salvage chemotherapy;
Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death
Keywords: مهار کننده پروتئازوم; Proteasome inhibitor; Tamoxifen derivative; Cell-penetrating peptide; Docking study;
Left Ventricular Dysfunction in Cancer Treatment
Keywords: مهار کننده پروتئازوم; anthracyclines; cancer treatment; cardiotoxicity; HER2-targeted therapy; LV dysfunction; ACCF; American College of Cardiology Foundation; AHA; American Heart Association; ASCO; American Society of Clinical Oncology; ASE; American Society of Echocardiograp
Suppressive Effect of Bortezomib on LPS-Induced Inflammatory Responses in Horses
Keywords: مهار کننده پروتئازوم; Horse; Endotoxemia; Proteasome inhibitor; Tumor necrosis factor-alpha; Nuclear factor-kappa B;
Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways
Keywords: مهار کننده پروتئازوم; Myeloma; Curcumin; Carfilzomib; NF-κB; p53; Proteasome inhibitor;
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Keywords: مهار کننده پروتئازوم; Carfilzomib; Clinical trial; Multiple myeloma; Newly diagnosed; Proteasome inhibitor;
Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells
Keywords: مهار کننده پروتئازوم; HSP90; Cleavage; Proteasome inhibitor; ROS; Caspase; VDUP1;
l-Tryptophan Schiff base cadmium(II) complexes as a new class of proteasome inhibitors and apoptosis inducers in human breast cancer cells
Keywords: مهار کننده پروتئازوم; l-Tryptophan; Cadmium Schiff base complex; Proteasome inhibitor; Apoptosis;
Proteasome Inhibitor-Loaded Micelles Enhance Antitumor Activity Through Macrophage Reprogramming by NF-κB Inhibition
Keywords: مهار کننده پروتئازوم; macrophage reprogramming; NF-κB; proteasome inhibitor; polymeric micelles; MG132; breast cancer;
The effect of proteasome inhibitor (AM114) on apoptosis in IL-1β-treated peripheral blood macrophage cultured cells from rheumatoid arthritis patients
Keywords: مهار کننده پروتئازوم; Apoptosis; Caspase-3; IL-1β-stimulated macrophages; Proteasome inhibitor; Rheumatoid arthritis;
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
Keywords: مهار کننده پروتئازوم; Combination therapy; Efficacy; Histone deacetylase inhibitor; Proteasome inhibitor; Safety;
A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor
Keywords: مهار کننده پروتئازوم; Carfilzomib; Degradation kinetics; Proteasome inhibitor; Stability indicating method; Stress test; UHPLC-UV- QTOF
3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies
Keywords: مهار کننده پروتئازوم; 3D-QSAR; Proteasome inhibitor; Pharmacokinetic; Cell cycle
Management of Carfilzomib-Associated Cardiac Adverse Events
Keywords: مهار کننده پروتئازوم; Cardiopulmonary; Clinical trials; Multiple myeloma; Proteasome inhibitor; Review;
Regulation of the TGF-β pathway by deubiquitinases in cancer
Keywords: مهار کننده پروتئازوم; AMSH; Associated molecule with SH3 domain proteases; AMSH-LP; Associated molecule with SH3 domain-like proteases; ATXN3; ataxin-3; ATXN3L; ataxin 3-like; BMPs; bone morphogenetic proteins; BRCC36; BRCA1/BRCA2-containing complex subunit 36; CHIP; carboxy t
Strongylophorines, meroditerpenoids from the marine sponge Petrosia corticata, function as proteasome inhibitors
Keywords: مهار کننده پروتئازوم; Strongylophorine; Meroditerpenoid; Petrosia corticata; Proteasome inhibitor;
Structure-activity relationship study of syringolin A as a potential anticancer agent
Keywords: مهار کننده پروتئازوم; Fmoc; 9-fluorenylmethyloxycarbonyl; EDCI; 1-ethyl-3-(3-dimethylaminopropyl)carboxamide; HOBt; 1-hydroxybenzotriazole; DMF; N,N-dimethylformamide; Proteasome inhibitor; Cancer; Structure-activity relationship;
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial
Keywords: مهار کننده پروتئازوم; HLA mismatch; Proteasome inhibitor; Allogeneic; Myeloablative; Transplantation; T cell replete;
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma
Keywords: مهار کننده پروتئازوم; Proteasome inhibitor; Anti-angiogenesis; Autophagy; Bortezomib resistance; Multiple myeloma; MM; multiple myeloma; CT-L; chymotrypsin-like; BM; bone marrow; UPS; ubiquitin-proteasome system; ANBL-6.WT; bortezomib sensitive ANBL-6 cell; ANBL-6.BR; bortez
Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6
Keywords: مهار کننده پروتئازوم; Radiation; Proteasome inhibitor; Autophagy; Endoplasmic reticulum stress; Pancreatic cancer
Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells
Keywords: مهار کننده پروتئازوم; Liver cancer; Proteasome inhibitor; Pin1; E2F1; Cell cycle; Huh7
Phenolic compounds stage an interplay between the ubiquitin-proteasome system and ubiquitin signal autophagic degradation for the ubiquitin-based cancer chemoprevention
Keywords: مهار کننده پروتئازوم; Phenolic compounds; Proteasome inhibitor; E1 inhibitor; DUB inhibitor; USP47; Autophagy inhibitor; 20S; 20S proteasome; DUB; deubiquitinating enzymes; E1; ubiquitin-activating enzyme; USP47; ubiquitin carboxy-terminal hydrolase 47; USP15; ubiquitin carbox
Preconditioning stimulus of proteasome inhibitor enhances aggresome formation and autophagy in differentiated SH-SY5Y cells
Keywords: مهار کننده پروتئازوم; PD; Parkinson's disease; UPS; ubiquitin-proteasome system.; Aggregates; Aggresome; Autophagy; Neurodegenerative disease; Preconditioning; Proteasome inhibitor;
Synthesis, crystal structure and anticancer activity of a novel ternary copper(II) complex with Schiff base derived from 2-amino-4-fluorobenzoic acid and salicylaldehyde
Keywords: مهار کننده پروتئازوم; BEEVGMHFIBPSGW-RFZNCAAWSA-LSchiff base; Copper(II) complex; Crystal structure; Anticancer activity; Proteasome inhibitor
Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy
Keywords: مهار کننده پروتئازوم; Bortezomib; Proteasome inhibitor; Membrane depolarization; Threshold tracking
Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors
Keywords: مهار کننده پروتئازوم; Proteasome inhibitor; Ubiquitin; E3 ligase; Deubiquitylase; Anticancer drugs
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model
Keywords: مهار کننده پروتئازوم; Bortezomib; Neuropathy; Cytokines; Chemotherapy-induced peripheral neuropathy; Proteasome inhibitor; Mice;
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924
Keywords: مهار کننده پروتئازوم; Leukemia; Proteasome; Immunoproteasome; Proteasome inhibitor; PR-924
La chimiothérapie cytotoxique
Keywords: مهار کننده پروتئازوم; Agent alkylant; agent du fuseau; Antimétabolite; Cancer; Chimiothérapie cytotoxique; Inhibiteur des topoisomérases; Inhibiteur du protéasome; OncologieAlkylating agent; Cancer; Cytotoxic chemotherapy; Metabolic inhibitor; Oncology; Proteasome inhibitor; S